Patents Examined by Venkataraman Balasubramanian
  • Patent number: 10174062
    Abstract: The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinsae activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: January 8, 2019
    Assignee: Metabasis Therapeutics, Inc.
    Inventors: Feng Tian, Qun Dang, G. Sridhar Prasad, Wenyu Li, Brett C. Bookser, Nicholas Brian Raffaele, Mark D. Erion
  • Patent number: 10172864
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
    Type: Grant
    Filed: December 28, 2016
    Date of Patent: January 8, 2019
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Zenon D. Konteatis, Janeta Popovici-Muller, Jeremy M. Travins, Robert Zahler, Zhenwei Cai, Ding Zhou
  • Patent number: 10177319
    Abstract: The present application relates to a polycyclic compound including nitrogen and an organic light emitting device including the same.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: January 8, 2019
    Assignee: HEESUNG MATERIAL LTD.
    Inventors: Young-Seok No, Kee-Yong Kim, Hyo-Kyun Ham, Jin-Seok Choi, Dae-Hyuk Choi, Sung-Jin Eum, Joo-Dong Lee
  • Patent number: 10174064
    Abstract: Energetic materials that are photoactive or believed to be photoactive may include a conventional explosive (e.g. PETN, nitroglycerine) derivatized with an energetic UV-absorbing and/or VIS-absorbing chromophore such as 1,2,4,5-tetrazine or 1,3,5-triazine. Absorption of laser light having a suitably chosen wavelength may result in photodissociation, decomposition, and explosive release of energy. These materials may be used as ligands to form complexes. Coordination compounds include such complexes with counterions. Some having the formula M(L)n2+ were synthesized, wherein M is a transition metal and L is a ligand and n is 2 or 3. These may be photoactive upon exposure to a laser light beam having an appropriate wavelength of UV light, near-IR and/or visible light. Photoactive materials also include coordination compounds bearing non-energetic ligands; in this case, the counterion may be an oxidant such as perchlorate.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: January 8, 2019
    Assignee: Triad National Security, LLC
    Inventors: David E. Chavez, Susan Kloek Hanson, Robert Jason Scharff, Jacqueline Marie Veauthier, Thomas Winfield Myers
  • Patent number: 10172824
    Abstract: The invention belongs to the field of medicine and chemical industry, and particularly relates to multiple crystal forms of scutellarin aglycone and preparation thereof. The invention also relates to use of said crystal forms of scutellarin aglycone in the manufacture of a medicament for preventing and/or treating a cardiovascular or cerebrovascular disease, rheumatic arthritis or stroke sequelae, etc. The crystal forms of scutellarin aglycone according to the invention have good stability, and can solve the problems concerning poor oral absorption and low bioavailability of scutellarin.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: January 8, 2019
    Assignees: YUNNAN INSTITUTE OF MATERIA MEDICA, HLK PHARMACEUTICALS CO., LTD.
    Inventors: Zeren Wang, Jun Xu, Minghui Wang, Zhaoyun Zhu, Jingkun Wang, Shuangxi Mei, Wenqiang Sun, Tao Cui
  • Patent number: 10167294
    Abstract: Described herein are fused bicyclic compounds, compositions, and methods for their use for the treatment of disease.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: January 1, 2019
    Assignee: Akarna Therapeutics, Ltd.
    Inventors: Raju Mohan, Benjamin Anthony Pratt
  • Patent number: 10160779
    Abstract: A process for preparing a compound of formula (I) or a salt thereof, the process comprising providing a compound of formula (III) wherein PG is an inert electron withdrawing hydroxyl protecting group, reacting the compound of formula (III) with a fluorinating agent, obtaining a compound of formula (II) and deprotecting the compound of formula (II).
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: December 25, 2018
    Assignee: Sandoz AG
    Inventors: Olga Schöne, Thorsten Wilhelm
  • Patent number: 10159677
    Abstract: The present invention provides a method for treating a disease, disorder or condition associated with GPR139 using compounds of formula 1: which are agonists of GPR139, certain compounds encompassed by formula 1, pharmaceutical compositions thereof, processes for making the compounds, and intermediates thereof.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: December 25, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Stephen Hitchcock, Betty Lam, Holger Monenschein, Holly Reichard
  • Patent number: 10155741
    Abstract: The present invention relates to compounds of formula I wherein R1? is methyl; R1 is methyl, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1? and R1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R2 is hydrogen, methyl, ethyl, isopropyl, tert-butyl, cyclopropyl, cyclopropylmethyl, or hydroxmethyl; R3 is Cl, F, CF3, methyl, methoxy, or cyclopropyl; R4 is hydrogen, methyl, F or Cl; X is N or CH; Y is N or CH; with the proviso that X and Y are not simultaneously CH; or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer. The compounds of formula I may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: December 18, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Marius Hoener, Juergen Wichmann
  • Patent number: 10155729
    Abstract: Reactor for the synthesis of melamine from urea, in accordance with the high-pressure non-catalytic process, comprising: a vertical reactor body (1), at least one inlet (2) for the urea melt, a set of heating elements (3), and a central duct (7), said set of heating elements (3) being arranged inside said central duct.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: December 18, 2018
    Assignee: Casale SA
    Inventor: Enrico Rizzi
  • Patent number: 10155775
    Abstract: The present application relates to a substituted amino six-membered saturated heteroalicycle represented by formula I as a long-acting DPP-IV inhibitor, a method for preparing the same, a pharmaceutical composition comprising the same, and a use of the same in treating and/or preventing diseases and disorders benefitting from DPP-IV inhibition.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: December 18, 2018
    Assignees: Centaurus Biopharma Co., Ltd., Chia Tai Tianqing Pharmaceutical Co., Ltd., Lianyungang Runzhong Pharmaceutical Co., Ltd.
    Inventors: Xinhe Xu, Yu Shen, Dengming Xiao, Hong Luo, Yong Peng, Yongxin Han, Aiming Zhang, Ling Yang
  • Patent number: 10155760
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: December 18, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guanglin Luo, Carolyn Diane Dzierba, John E. Macor
  • Patent number: 10150766
    Abstract: The present invention is directed to compounds of Formula (I), which includes enantiomer and diasteromers thereof: The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.
    Type: Grant
    Filed: August 25, 2015
    Date of Patent: December 11, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Michael A. Letavic, Jason C. Rech, Jessica L. Wall
  • Patent number: 10143692
    Abstract: Polymorphs of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine are provided herein. Processes for preparing the polymorphs and pharmaceutical composition comprising the polymorphs are also disclosed.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: December 4, 2018
    Assignee: Array BioPharma Inc.
    Inventors: Donald T. Corson, Christopher M. Lindemann, Daniel J. Watson
  • Patent number: 10144739
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R4, R7, A, D, E, F, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: December 4, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Gollner, Joachim Broeker, Nina Kerres, Christiane Kofink, Juergen Ramharter, Harald Weinstabl
  • Patent number: 10138391
    Abstract: A fluorinated compound represented by D1-Rf1—O—CH2—(CmF2mO)n-A (wherein D1 is CF3— or CF3—O—, Rf1 is a C1-20 fluoroalkylene group containing at least one hydrogen atom, a C2-20 fluoroalkylene group containing at least one hydrogen atom and having an etheric oxygen atom between carbon-carbon atoms, etc., m is an integer of from 1 to 6, n is an integer of from 1 to 200, and A is a monovalent organic group having at least one (meth)acryloyl group), which is capable of imparting excellent antifouling properties (oily ink repellency, fingerprint stain removability) and lubricity to e.g. a hard coat layer; a hard coat layer-forming composition which contains such a fluorinated compound; and an article having a hard coat layer formed from such a composition.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: November 27, 2018
    Assignee: AGC Inc.
    Inventors: Kiyotaka Takao, Toyomichi Shimada, Taiki Hoshino
  • Patent number: 10137130
    Abstract: Provided are methods and compositions for treating cancers in patients carrying an IDH1 mutation or IDH2 mutation.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: November 27, 2018
    Assignees: Celgene Corporation, Agios Pharmaceuticals, Inc.
    Inventors: Michael Amatangelo, Xiaolan Hu, Anjan Thakurta, Sung Eun Choe, Bin Wu
  • Patent number: 10138247
    Abstract: A compound of the general formula (I) wherein Y represents —CH2— or >C=0; R1 is selected from the group consisting of A1, A2 and A3; R2 represents dioxothiomorpholino moiety B1, piperazinyl moiety B2, azetidinyl moiety B3, or piperidinyl moiety B4; R3 is selected from the group consisting of H, halogen, and C1-C4 alkyl; R4 is selected from the group consisting of C1-C4 alkyl, C3-C4-cycloalkyl, C1-C4 alkyl substituted with C1-C4 alkoxy, and CHF2, and their pharmaceutically acceptable salts. Pharmaceutical compositions comprising said compounds and their use in the treatment of diseases of immune system, inflammatory diseases and cancer.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: November 27, 2018
    Assignee: CELON PHARMA, S.A.
    Inventors: Barbara Dymek, Marcin Zagozda, Maciej Wieczorek, Krzysztof Dubiel, Aleksandra Stanczak, Daria Zdzalik, Pawel Gunerka, Mariola Sekular, Maciej Dziachan
  • Patent number: 10138250
    Abstract: The present invention relates to novel crystalline forms of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide (compound I), its salts, and process for preparation thereof. Crystalline forms in the present invention have good stability, low hygroscopicity, good processability, easy treatability and other favorable properties. In addition, the process is simple, low cost, and has an important value for future optimization and development of the drug.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: November 27, 2018
    Assignee: Crystal Pharmatech Co., Ltd.
    Inventors: Minhua Chen, Yanfeng Zhang, Xiaoyu Zhang
  • Patent number: 10135008
    Abstract: A novel Pt tetradentate complexes having Pt—O bond is disclosed. These complexes are useful as emitters in phosphorescent OLEDs.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: November 20, 2018
    Assignee: Universal Display Corporation
    Inventors: Chun Lin, Chuanjun Xia, Jui-Yi Tsai